医学
可穿戴计算机
心脏病学
植入式心律转复除颤器
医疗急救
心力衰竭
除颤
可穿戴技术
心脏骤停
梅德林
重症监护医学
内科学
作者
Christopher C. Cheung,Jeffrey E. Olgin,Byron K. Lee
标识
DOI:10.1016/j.tcm.2020.03.002
摘要
The wearable cardioverter-defibrillator (WCD) was first approved for clinical use in 2002, and is routinely used in select populations at high risk for sudden cardiac death. WCDs are frequently considered as a bridge to definitive therapy or in circumstances where insertion of conventional implantable cardioverter-defibrillators (ICD) is temporarily contraindicated. In this review, we summarize the literature on WCDs. From prospective trials to the first randomized controlled trial with WCD, there is a growing body of evidence that suggests that the WCD is safe and effective. In the first randomized controlled trial of the WCD (VEST Trial), there was no reduction in arrhythmia death but there was a reduction in all-cause mortality. We discuss the mortality impact, rate of inappropriate shocks, compliance, and potential quality of life implications with the WCD. Finally, we present the evidence for WCD use in select populations (e.g., post-myocardial infarction, device extraction), and the current guideline recommendations for WCD use.
科研通智能强力驱动
Strongly Powered by AbleSci AI